Free Newsletter
India forecasts fast-paced growth in stem cell research
Following the Obama administration's decision to loosen the purse strings on federal support of stem cell research, scientists at the Stem Cell Research Forum of India expect discovery work in the subcontinent to barrel ahead to an estimated $540 million next year with an annual growth rate of 15 percent.
"India is a cheaper alternative for research and clinical trials. The country is not too far behind the US in terms of practical aspects of stem cells. Many companies are eyeing India because of its huge population base and genetic versatility," said Karan Goel, founder and chairman of Stem Cell Global Foundation.
Vishwa Mohan Katoch, the director general of the Indian Council of Medical Research, said the council plans to develop new collaborations with U.S. institutions. "It's important to develop the public-private partnership in the field of stem cell research and therapy, as it has a direct impact on the translation of technology. You may see many such partnerships in future."
"There are several laboratories that are researching stem cells. A lot of this is tailored to address diseases that are important in the local context and this stimulates innovation," said Maneesha Inamdar, associate professor for vascular biology laboratory and stem cell laboratory at the Jawaharlal Nehru Centre for Advanced Scientific Research.
- read the article from Economic Times
Related Articles:
India's biotech industry grows at 20% clip
India drawing more clinical trials
India plots 20 new biotech parks
India's biopharma surges on outsourcing boom
India passes U.K. in number of science PhDs
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: